---
title: "PLOS One Editorial Note: Concerns About Peer Review for NOXA/Bax‑Smac Cisplatin Sensitivity Study"
id: "plos-one-11-editorial-note-noxa-induced-alterations-in-the-bax-smac-axis-enhance"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-11-editorial-note-noxa-induced-alterations-in-the-bax-smac-axis-enhance"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761"
published_at: "2026-07-28T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PLOS One Editorial Note: Concerns About Peer Review for NOXA/Bax‑Smac Cisplatin Sensitivity Study
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-11-editorial-note-noxa-induced-alterations-in-the-bax-smac-axis-enhance
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761)
- **Published At:** 2026-07-28T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The PLOS One Editors issued an **Editorial Note** for the article titled “NOXA‑induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin.” - The Editorial Note was published on July 28, 2026, and is indexed with DOI 10.1371/journal.pone.0354761. - The stated reason for the note is **concerns related to the peer review process** for that article; readers are advised to interpret the article with caution. - The note cites the original research article (Lin et al., PLoS One 2012;7(5):e36722) and a linked correction published in 2012. - The Editorial Note reiterates that such notes provide information that may affect an article’s interpretation and that readers should consider these concerns when assessing the findings. - The document is open access and distributed under the Creative Commons Attribution License (CC BY 4.0); full citation and licensing details are provided in the note. - Details about the specific peer review concerns, any investigatory steps, or further editorial actions were not reported in the Editorial Note and therefore are not available in the source.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0354761) * * About * Browse * Publish * [](https://journals.plos.org/plosone/ "PLOS One") * Search [advanced search](https://journals.plos.org/plosone/search) * [Browse Topics](https://journals.plos.org/plosone/subjectAreaBrowse) Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click [here](https://github.com/PLOS/plos-thesaurus/blob/master/README.md "Link opens in new window"). [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761) [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761) * 0 [Save](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#savedHeader) * 0 [Citation](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#citedHeader) * 22 [View](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#viewedHeader) * 0 [Share](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761#discussedHeader) Open Access Editorial Note Editorial Notes are published by PLOS to provide readers information relevant to an article’s interpretation. [See all article types » ](https://journals.plos.org/plosone/s/other-article-types) # Editorial Note: NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin * The PLOS One Editors # Editorial Note: NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin * The PLOS One Editors ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: July 28, 2026 * * [Article](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761) * [Metrics](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0354761) * [Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0354761) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pone.0354761) * [References](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761#references) * [Reader Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0354761) The _PLOS One_ Editors issue this Editorial Note for this article [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761#pone.0354761.ref001),[2](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761#pone.0354761.ref002)] because of concerns related to the peer review process. Readers are encouraged to approach the article [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761#pone.0354761.ref001)] with careful consideration. ## References 1. 1. Lin C, Zhao X, Li L, Liu H, Cao K, Wan Y, et al. NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin. PLoS One. 2012;7(5):e36722. pmid:22590594 * [ View Article ](https://doi.org/10.1371/journal.pone.0036722 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/22590594 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=NOXA-induced+alterations+in+the+Bax%2FSmac+axis+enhance+sensitivity+of+ovarian+cancer+cells+to+cisplatin+Lin+2012 "Go to article in Google Scholar") 2. 2. Lin C, Zhao X-y, Li L, Liu H-y, Cao K, Wan Y, et al. Correction: NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin. PLoS One. 2012;7(8):10.1371/annotation/a863b4b3-6d4c-447a-87e3-4d631ceb7a46. pmid:22590594 * [ View Article ](https://doi.org/10.1371/annotation/a863b4b3-6d4c-447a-87e3-4d631ceb7a46 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/22590594 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Correction%3A+NOXA-Induced+Alterations+in+the+Bax%2FSmac+Axis+Enhance+Sensitivity+of+Ovarian+Cancer+Cells+to+Cisplatin+Lin+2012 "Go to article in Google Scholar") **Citation:** The _PLOS One_ Editors (2026) Editorial Note: NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin. PLoS One 21(7): e0354761. https://doi.org/10.1371/journal.pone.0354761 **Published:** July 28, 2026 **Copyright:** © 2026 The PLOS One Editors. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. [Download PDF](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0354761&type=printable) * [Citation](https://journals.plos.org/plosone/article/citation?id=10.1371/journal.pone.0354761) * [XML](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0354761&type=manuscript) [Print](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354761) Share * [![Reddit](https://journals.plos.org/resource/img/icon.reddit.16.png)Reddit](https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0354761 "Submit to Reddit") * [![Facebook](https://journals.plos.org/resource/img/icon.fb.16.png)Facebook](https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0354761&t=Editorial%20Note:%20NOXA-Induced%20Alterations%20in%20the%20Bax/Smac%20Axis%20Enhance%20Sensitivity%20of%20Ovarian%20Cancer%20Cells%20to%20Cisplatin "Share on Facebook") * [![LinkedIn](https://journals.plos.org/resource/img/icon.linkedin.16.png)LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0354761&title=Editorial%20Note:%20NOXA-Induced%20Alterations%20in%20the%20Bax/Smac%20Axis%20Enhance%20Sensitivity%20of%20Ovarian%20Cancer%20Cells%20to%20Cisplatin&summary=Checkout%20this%20article%20I%20found%20at%20PLOS "Add to LinkedIn") * [![Mendeley](https://journals.plos.org/resource/img/icon.mendeley.16.png)Mendeley](https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0354761 "Add to Mendeley") * [![Bluesky](https://journals.plos.org/resource/img/icon.bluesky.light.png)Bluesky](https://bsky.app/intent/compose?text=Checkout%20this%20article%20I%20found%20at%20PLOS:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0354761 "Share on Bluesky") * ![Email](https://journals.plos.org/resource/img/icon.email.16.png)Email ![Check for updates via CrossMark](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg) ### Related PLOS Articles * **COMMENTARY pertains to** * NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin * [View Page](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0036722) * [PDF](https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0036722 "PDF opens in new window") Advertisement * [Publications](https://plos.org/our-journals/) * [PLOS Aging and Health](https://journals.plos.org/agingandhealth/) * [PLOS Biology](https://journals.plos.org/plosbiology/) * [PLOS Climate](https://journals.plos.org/climate/) * [PLOS Complex Systems](https://journals.plos.org/complexsystems/) * [PLOS Computational Biology](https://journals.plos.org/ploscompbiol/) * [PLOS Digital Health](https://journals.plos.org/digitalhealth/) * [PLOS Ecosystems](https://journals.plos.org/ecosystems/) * [PLOS Genetics](https://journals.plos.org/plosgenetics/) * [PLOS Global Public Health](https://journals.plos.org/globalpublichealth/) * [PLOS Medicine](https://journals.plos.org/plosmedicine/) * [PLOS Mental Health](https://journals.plos.org/mentalhealth/) * [PLOS Neglected Tropical Diseases](https://journals.plos.org/plosntds/) * [PLOS One](https://journals.plos.org/plosone/) * [PLOS Pathogens](https://journals.plos.org/plospathogens/) * [PLOS Sustainability and Transformation](https://journals.plos.org/sustainabilitytransformation/) * [PLOS Water](https://journals.plos.org/water/) * [Home](https://plos.org) * [Blogs](https://blogs.plos.org) * [Collections](https://collections.plos.org/) * Give feedback * [LOCKSS](https://journals.plos.org/plosone/lockss-manifest) * [Privacy Policy](https://plos.org/privacy-policy) * [Terms of Use](https://plos.org/terms-of-use) * [Advertise](https://plos.org/advertise/) * [Media Inquiries](https://plos.org/media-inquiries) * [Contact](https://plos.org/contact) ![PLOS](https://journals.plos.org/resource/img/logo-plos-footer.png) PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in California, US ![PLOS Logo](data:image/svg+xml;charset=utf-8;base64,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) ### Cookie Preference Center Our website uses different types of cookies. Optional cookies will only be set with your consent and you may withdraw this consent at any time. Below you can learn more about the types of cookies PLOS uses and register your cookie preferences. Accept All Cookies ### Customize Your Cookie Preference +**Strictly Necessary** Always On +**Functional** OnOff +**Performance and Analytics** OnOff +**Marketing** OnOff Save Selected Preferences and Close [For more information about the cookies and other technologies used by us, please read our Cookie Policy.](https://plos.org/cookies-policy)
## Related Clinical Research

- [SIRT6 modulation of Nrf2 enhances cisplatin response in lung cancer models](https://medichelpline.com/clinical-feed/pubmed-42727479.md) (DOI: 10.1016/j.bbrc.2026.154563)
- [SRSF1 controls transcription and alternative splicing to alter p53 signaling and genome maintenance](https://medichelpline.com/clinical-feed/biorxiv-4-srsf1-coordinates-transcription-and-alternative-splicing-to-modulate-p53-and.md)
- [Neoadjuvant strategies for locally advanced head and neck squamous cell carcinoma](https://medichelpline.com/clinical-feed/pubmed-42885303.md) (DOI: 10.3892/or.2026.9210)
- [AKNA as a Prognostic Biomarker in Endometrial Cancer: STING Activation and Macrophage Reprogramming](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-akna-serves-as-a-prognostic-biomarker-and-restrains-endometrial-cancer.md)
- [Bioengineered microRNAs (miR-124, miR-34a) sensitize high-risk neuroblastoma to cisplatin](https://medichelpline.com/clinical-feed/biorxiv-23-synergistic-combination-of-bioengineered-microrna-and-chemotherapy-across-high.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.